



CELLA SPACE LIMITED

CIN:L93000KL1991PLC006207

Regd Office: "SREE KAILAS", 57/2993-94, PALIAM ROAD, ERNAKULAM, COCHIN- 682 016

Phone: (0484) 2382182, E-mail: secretary@sreekailas.com, Website: www.sreekailas.com

20th January 2025

To
The Manager
Listing Department
BSE Limited
Phiroze JeeJeebhoy Towers
Dalal Street, Mumbai 400001

Dear Sir/ Madam,



| | |
|-------------|--|
| Sub: | Newspaper Publication regarding Standalone Audited Financial Results for the Quarter and nine months ended December 31, 2024 – Pursuant to Regulation 47 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. |
|-------------|--|

Enclosed herewith the Newspaper Publication regarding Standalone Unaudited Financial Results for the quarter and nine months ended December 31, 2024 published in "Financial Express" & "Deepika" on January 19, 2025. The results were approved by the Board of Directors at their meeting held on January 18, 2025.

Requesting to kindly take note of the same.

Thanking You

For Cella Space Limited

S Rajkumar (DIN: 01790870)
Vice Chairman & Managing Director

RG KAR RAPE-MURDER VERDICT

Court finds accused Sanjay Roy guilty

Quantum of sentence to be declared Monday

PRESS TRUST OF INDIA Kolkata, January 18

A KOLKATA COURT on Saturday declared Sanjay Roy "guilty" of raping and murdering an on-duty doctor at the state-run RG Kar Medical College and Hospital, a heinous crime that sparked nationwide outrage and prolonged protests.

The Sealdah court, where Roy's trial was held, will declare his sentence on Monday, Anirban Das, the additional district and sessions judge, said.

The judgment was pronounced nearly two months after the in-camera trial commenced in November last year and 162 days after the heinous crime was committed on August 9, 2024. Roy was found guilty under Sections 64 of the Bharatiya Nyaya Sanhita that governs rape, and Sections 66 and 103 (1) of the Act, which deals with punishments for death and murder.

Section 103 (1) of BNS entails a possible punishment of death or life imprisonment.

The judge stated that Roy was found guilty of sexually assaulting the doctor and strangling her to death, and that the CBI had proven all the charges against him. Das said Roy's statement will be heard at 12.30 pm on Monday, and the sentence will be pronounced thereafter.

At the time of the delivery of the verdict, Roy claimed in court that he was framed. In his defence, Roy said, "I wear a rudraksh necklace, and if I had committed the crime, it would have snapped." After the judgement, police whisked away Roy from the courtroom to the Presidency Correctional Home under strict vigil, preventing the waiting



Police personnel keep vigil as accused Sanjay Roy is brought to the Sealdah court in Kolkata on Saturday

Won't rest until all accused are punished, says victim's mother

WELCOMING THE CONVICTION of prime accused Sanjay Roy by a trial court here in the RG Kar Medical College rape-murder case, the mother of the deceased woman doctor on Saturday said they were still waiting for the other criminals to be arrested and punished.

"That Sanjay is guilty was proved through biological evidence. And that he stood silent during the trials in the court also proved his hand in torturing and killing my daughter. But he was not alone, there are

media persons from attempting any kind of interaction with the convict. The medic's parents thanked the judge for the guilty verdict and said the court honoured the trust they had reposed in it.

In its chargesheet, the CBI had mentioned Roy, a civic volunteer with the city police, as the prime and sole suspect of the crime, and he had committed the murder of the postgraduate trainee at the state-run hospital. The Kolkata Police, which was investigating the case initially, arrested Roy on August 10, a day after the medic's body was

others who haven't been arrested yet. So, justice hasn't been delivered," the victim's mother told PTI soon after the court convicted Roy.

She said she and her husband would continue their fight for justice till the last day of their lives. "The case is not complete. It will only be completed after the others who were involved in killing our daughter are punished. We will wait for that day... Till that day, we will not be able to sleep," she said. — PTI

recovered from the seminar room of the hospital. The Calcutta High Court later transferred the case to the CBI, which had sought death penalty for the accused. The in-camera trial in the rape and murder of the doctor commenced on November 12, and 50 witnesses were examined. Hearing of the trial concluded on January 9. The crime led to nationwide outrage and prolonged protests by junior doctors in Kolkata, demanding justice for the victim and stronger security arrangements in state-run hospitals.

Wegovy...

Interestingly, celebrities like Elon Musk, Oprah Winfrey and Amy Schumer, among others, have also endorsed drugs like Ozempic after using them for weight loss. In India, too, the weight loss transition of celebrities like Karan Johar, Kusha Kapila, Tanmay Bhat, etc, have been linked to Ozempic, though they have denied taking these medicines. "As per the India Economic Survey 2024, obesity is a serious concern among India's adult population, with the adult obesity rate having more than tripled. It is critical that people with obesity are able to access comprehensive care that can prevent and treat the disease," the Eli Lilly spokesperson told FE.

Sensing the shake-up this will bring to the Indian pharma sector, domestic pharma companies are also in a race to come up with alternatives or prototype versions of these drugs that are more economical, more accessible, or have exclusivity benefits.

Sun Pharma is working on an anti-obesity drug utreglutide. Cipla is coming up with a generic and affordable version of Wegovy, and is eyeing a deal with Eli Lilly to market its drug in the country. Dr Reddy's Laboratories is also coming up with a generic version of Wegovy. Biocon, on the other hand, is working on GLP-1 therapies, and has got an approval for liraglutide. Similar to Cipla, Natco Pharma is also developing a generic version of Ozempic. The interest in these drugs is justified. In 2022, the WHO had stated that one in eight people in the world lived with obesity—and that obesity was responsible for 44% of all diabetes cases, 23% of ischemic heart diseases, and 7-41% of all cancer cases.

A 2024 Lancet study focused on India found that at least 44 million women and 26 million men who were over 20 years old, were clinically obese. While there's no specific data on how many people with obesity need surgical intervention or medication in India, Dr Anoop Misra, executive chairman and director, diabetes and endocrinology, Fortis C-Doc Hospital for Diabetes and Allied Sciences, told FE that most patients with obesity are prescribed medication, adding, "More and more patients are coming with queries regarding anti-obesity medications now that they have become aware of it."

The scale of the problem is such that after all the acclaim that these drugs received, people were travelling to foreign countries to access them, resorting to grey markets, and even getting these imported from Europe, in a phenomenon dubbed 'Ozempic tourism' because of this huge scale, Eli Lilly said

Mass car makers in luxury lane

"IT'S AN INTERNEE-CONNECTED car in which customers can pay for EV charging directly from the car's infotainment system at more than 1,150 charging points," said Garg.

Maruti Suzuki's eVitarā—to be launched later this year—will get a digital cockpit with a 10.1-inch integrated display and a 10.25-inch multi-information display. It also has ambient lighting, fixed-glass sunroof, 10-way adjustable seat, and other features earlier found only in luxury cars from Mercedes-Benz, BMW, and others. But even as mass-market carmakers are introducing luxury features, the traditional luxury players are upping their game both in terms of affordability but more importantly curated experiences.

BMW, for instance, launched the X1 Long Wheelbase electric for just ₹49 lakh—India's most affordable luxury EV. Vikram Pawah, president & CEO, BMW Group India, told FE that the X1 electric is for the

new Bharat customer. "People are becoming more aspirational. Owing a luxury car such as a BMW shouldn't be a long-term dream—you can have it now. The X1 electric is for such buyers—it's comfortable, spacious, luxurious, has good performance and road presence, ground clearance suitable for Indian roads, and is a sustainable and value-for-money car," he said. "But BMW will maintain its edge—especially in terms of luxury experiences we provide to our customers." BMW buyers get access to the carmaker's Excellence Club, which provides them personalised luxury experiences such as curated drives, high-end dinners, access to golf events and art shows, and so on. "We curate experiences that money can't buy—let's say flying in a masterchef from abroad and giving them a culinary experience," Pawah said. Mercedes-Benz has collaborated with Tata Cliq to retail its 'luxury collection' items. Called the 'House of Mercedes-Benz', it comprises

exclusive genuine merchandise and accessories like apparel, bags, footwear, sunglasses, perfumes and watches. "A luxury car buyer just doesn't buy a car, but wants to involve with the brand. That's what makes him feel valued," Santosh Iyer, MD & CEO, Mercedes-Benz India, told FE.

Tanmay Bhattacharya, executive vice-president of Lexus—the luxury car arm of Toyota—told FE that even as luxury features are being democratised, luxury carmakers will always stand out because of the curated experiences they provide. "Lexus is famous globally for two things—the best car technology and Omotenashi (Japanese hospitality). Omotenashi means providing guests (our customers and even prospective customers) not only with what they love, but also anticipating their needs and fulfilling them," he said. "Instead of chasing sales numbers, we make sure that every Lexus customer is treated in the best possible manner, and that what makes us stand out."

their "pricing strategy in India will reflect the medicine's efficacy and the significant value it brings in reducing the overall health and economic burden of type 2 diabetes and obesity". The company's spokesperson added that however, "we have not yet finalised the pricing of tirzepatide". In the US, without insurance, Wegovy can cost around \$1,350, Ozempic can cost around \$968, and Zepbound (or tirzepatide) can cost around \$1,060 for a month's supply.

But would insurance companies in India cover these medications, Pankaj Nawani, CEO of CarePal Secure, a medical insurance provider, said, "Traditionally, health insurance policies in India exclude obesity treatments, considering them lifestyle-related rather than medically necessary. This stance may evolve as obesity gains recognition as a chronic condition linked to severe comorbidities, which already qualify for coverage."

Nawani goes on to add that insurance coverage will depend on other factors as well—regulatory clearance from the Central Drugs Standard Control Organisation, doctors prescribing these drugs for managing obesity-related complications rather than for weight loss alone, competitive pricing, etc. "A shift in public health narratives toward preventive care may encourage insurers to reconsider their stance, particularly if these

drugs demonstrate cost savings by mitigating long-term healthcare expenditures," Nawani told FE.

The biggest benefit of these drugs would, of course, be to the patients. Dr Ambrish Mithal, chairman and head of endocrinology and diabetes at Max Healthcare, Delhi, explained, "The existing anti-obesity drug choice in India is poor. Patients would take orlistat, sibutramine, etc, which weren't very effective or potent and had a lot of side effects. But the way these drugs work, especially the GLP-1 pathway, is exciting." Interestingly, a lot of people would qualify as candidates for these drugs too. Since Eli Lilly and Novo Nordisk are both essentially making anti-diabetic drugs that also have strong weight loss properties, the first candidates would be patients with type 2 diabetes. Dr Mithal added that people with severe obesity and out of control weight problems that are causing co-morbidities like sleep apnea and osteoarthritis, would be prescribed these drugs too. "But patients who have a medical history of pancreatitis and thyroid cancer in the family will not be prescribed any of these drugs," Dr Mithal went on to say.

EPFO simplified


Additionally, the EPFO has eased the process of 'joint declaration' on the portal by allowing employee to self-correct most common errors in his personal details, like name, date of birth, gender, nationality, etc, without

any verification by employer or approval by EPFO, if the universal account number (UAN) was issued after October 1, 2017 (when Aadhaar matching was made mandatory). No supporting document is required in such cases, said the sources. If the UAN was issued prior to October 1, 2017, any correction can be made by the employer without the EPFO approval, and the requirement of supporting documents has also been simplified for such cases, they said. In cases, where UAN is not linked with Aadhaar, any correction would have to be submitted physically to the employer, and after verification forwarded to EPFO for approval. At present, around 27% of the grievances filed by the members relate to member profile/KYC issues which would significantly reduce now, said the sources.

Kotak Mahindra

"The rate of deterioration has come down significantly and that's why it gives us comfort that in the next two-three quarters, the stress in MFI business will plateau and start coming down," said Ashok Vaswani, CEO, Kotak Mahindra Bank, in an earnings call. The bank's advances increased by 16% Y-o-Y to ₹4.33 lakh crore as of December 31, 2024. Unsecured retail advances (including retail micro credit) as a percentage of net advances stood at 10.5% as on December 31, 2024. The bank's net interest margin (NIM) improved to 4.93% in the December quarter from 4.91% in September quarter, but was lower than 5.22% in the year-ago period. The improve-

REPORT CARD



ment in the NIMs was because of an increase in current accounts and a rate cut in savings account, leading to sustainable growth in the NIMs, said group chief financial officer Devang Gheewalla.

Fresh slippages, or the proportion of standard loans turning bad, fell to ₹1,657 crore during the quarter from ₹1,875 crore a quarter ago. Average total deposits grew by 15% Y-o-Y to ₹4.58 lakh crore at the end of December 2024. The current account-savings account ratio was 42.3% at the end of December, against 43.6% a quarter ago and 47.7% a year ago. The bank improved asset quality as its gross non-performing assets (GNPA) stood at 1.5% in the December quarter of the current fiscal compared to 1.73% in the same quarter last year. Net NPA came at 0.41% versus 0.34% last year. The bank's total provision for the quarter was ₹6,634 crore as compared to ₹6,963 crore in the year-ago period.

2028 Olympics

"Currently the full focus must be on the fight against the fires and the protection of the people and property," Los Angeles was awarded the 2028 Olympics for a third time in 2017, with the IOC praising organisers' bid for using existing and temporary venues rather than constructing new stadiums and sports facilities specifically for the Games. Yet the Games were still expected to cost roughly \$6.9 billion for investments like upgraded transportation, revamped facilities and improvements to the city's infrastructure. No one counted on a large-scale disaster occurring in the nation's second-largest city when those projects were approved. "What's happened in a number of recent Olympics is something else comes along that entirely changes what the Games are all about," said Dr Matthew Brown, a University of Utah professor. "Something like wildfires can really change the priorities of lots of cities and what they fund and when they want to fund it," Brown said.

Table with financial data for Cella Space Limited, including Standalone and Consolidated results for Quarter Ended 31st December 2024.

Advertisement for Travancore Titanium Products Limited, featuring an E-Tender Notice for the loading and transportation of HCL.

SIGACHI INDUSTRIES LIMITED 229/1 & 9, Kalyan's Tulsiram Chambers, Madinaguda, Hyderabad, Telangana. CIN: L24110TG1989PLC009497

Table showing Extract of unaudited financial results of Sigachi Industries Limited and its subsidiaries for the quarter and nine months period ended 31 December 2024.

Notes: 1. The above is an extract of the detailed format of Standalone and Consolidated Unaudited Financial Results for the quarter and nine months period ended 31st December, 2024. The same have been reviewed by the Audit Committee and were taken on record by the Board of Directors in their respective meetings held on 18.01.2025. The Statutory Auditors of the company have carried out a Limited review of the aforesaid results.

Place: Hyderabad Date: 18-01-2025 For Sigachi Industries Limited Sd/- Amit Raj Sinha Managing Director & CEO, (DIN: 01263292)

Form A Public Announcement for the attention of creditors of Indian Technometal Company Limited, including details of the insolvency process and creditor instructions.

PM Modi distributes 6.5 million Svamitva property cards



PM Modi speaks during distribution of property cards via video conferencing

PRIME MINISTER NARENDRA Modi on Saturday distributed more than 65 lakh property cards under the Svamitva scheme, and said it will bolster economic activities and help in poverty alleviation.

The prime minister virtually addressed the event and also interacted with some beneficiaries. He also said rural land digitisation is "furthering rural empowerment by leveraging the power of technology and good governance". The property cards are being distributed to beneficiaries across more than 50,000 villages in 10 states—Chhattisgarh, Gujarat, Himachal Pradesh, Madhya Pradesh, Maharashtra, Mizoram, Odisha, Punjab, Rajasthan, Uttar Pradesh and two Union territories of Jammu and Kashmir, and Ladakh. Modi said the scheme will help people get loans and benefits of other government schemes. —PTI

